Semaglo 0.25mg Subcutaneous Injection

Composition

Semaglutide 0.25 mg/0.188 ml

Semaglutide 0.25mg Subcutaneous Injection is indicated for:

• Lowering blood sugar levels in adults with type 2 diabetes mellitus.
• Preventing serious diabetes-related complications such as kidney damage and blindness.
• Reducing the risk of heart attack or stroke in people with type 2 diabetes.

Common Side Effects

• Nausea
• Diarrhea
• Vomiting
• Decreased appetite
• Fatigue
• Constipation

Pharmacology

Semaglutide 0.25mg Subcutaneous Injection contains Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 agonists help to:

• Stimulate insulin production.
• Suppress glucagon secretion.
• Reduce appetite, which can lead to weight loss.

Lifestyle Recommendations

• Maintain a healthy diet.
• Engage in regular physical activity.
• Monitor blood sugar levels regularly.

Emergency Measures

• In case of severe hypoglycemia, have a fast-acting glucose source readily available.
• If experiencing symptoms like blurred vision, dizziness, or drowsiness due to blood sugar fluctuations, avoid driving or operating machinery until symptoms resolve.

Risk of Hypoglycemia

• Particularly when used with insulin or sulfonylureas. To mitigate risk, have regular meals and carry a fast-acting source of glucose.

Dosage:

Adult Dose for Type 2 Diabetes Mellitus:

• Initial Dose: 0.25 mg subcutaneously once weekly for the first 4 weeks.
• Maintenance Dose:
  • Increase to 0.5 mg once weekly after the initial 4 weeks.
  • If glycemic control is not achieved with 0.5 mg, increase to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose.

Hepatic Impairment: No dosage adjustment is required.

Child Dose:

• <18 years: Safety and efficacy not established.

Renal Dose:

• Renal Impairment: No dosage adjustment is required.

Administration:

• Inject subcutaneously in the abdomen, thigh, or upper arm.
• Administer at any time of the day, with or without meals.
• If a dose is missed, administer it within 5 days. If more than 5 days have passed, skip the missed dose and continue with the regular schedule.

Composition

• 0.25 mg Injection: Each pre-filled syringe contains Semaglutide 0.25 mg in 0.5 ml solution.
• 0.50 mg Injection: Each pre-filled syringe contains Semaglutide 0.50 mg in 0.5 ml solution.
• 1 mg Injection: Each pre-filled syringe contains Semaglutide 1 mg in 0.5 ml solution.
• 1.7 mg Injection: Each pre-filled syringe contains Semaglutide 1.7 mg in 0.75 ml solution.
• 2.4 mg Injection: Each pre-filled syringe contains Semaglutide 2.4 mg in 0.75 ml solution.

Mechanism of Action:

• Enhances Glucose-Dependent Insulin Secretion: By activating GLP-1 receptors on pancreatic beta cells, Semaglutide stimulates insulin secretion in response to elevated blood glucose levels.
• Suppresses Elevated Glucagon Secretion: Semaglutide reduces the secretion of glucagon from pancreatic alpha cells, which helps lower blood glucose levels by reducing hepatic glucose production.
• Slows Gastric Emptying: This delay in gastric emptying contributes to reduced postprandial glucose levels and aids in weight management by increasing satiety.

Special Populations

• Pregnancy & Lactation: Consult a doctor before use. Not recommended during pregnancy. If planning pregnancy, discontinue at least 2 months before.
• Pediatric Use: Safety and efficacy not established in patients under 18 years of age.

Contraindications

• Hypersensitivity to Semaglutide or any component of the formulation.

Precautions & Warnings

• Diabetic Ketoacidosis: Not suitable for patients with type 1 diabetes or those with diabetic ketoacidosis.
• Pancreatitis: Discontinue use if pancreatitis is suspected.
• Gastrointestinal Issues: Use with caution in patients with a history of severe gastrointestinal disease.
• Hypoglycemia: Increased risk when used with insulin or sulfonylureas.

Storage

• Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Do not freeze.